RxDoctor Payments Data

Matthew Daniels, MD

Internal Medicine · Pensacola, FLNPI 1790737039

Payments from drug & device makers

$931in general payments, 2019–2025

Across 57 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$243
  • Novo Nordisk$160
  • GSK$148
  • Novartis$77
  • Abbott$58
  • Amgen$54
  • plus $191 from 8 others

What the payments were for

  • Food & beverage$92599%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$931 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$88,058
Medicare patients
428
Services billed
1,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$95,245
EliquisApixaban83$88,554
TrulicityDulaglutide72$84,280
JardianceEmpagliflozin78$67,736
FarxigaDapagliflozin Propanediol64$55,879
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$36,172
MounjaroTirzepatide27$28,317
CreonLipase/Protease/Amylase20$24,682
LinzessLinaclotide42$22,816
Bydureon BciseExenatide Microspheres18$22,280
EntrestoSacubitril/Valsartan22$21,925
Tresiba Flextouch U-200Insulin Degludec14$20,099
MyrbetriqMirabegron32$18,467
Tresiba Flextouch U-100Insulin Degludec17$17,596
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$14,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$37$112,59799 claims
Novo NordiskOzempic, Rybelsus$160$106,19883 claims
PfizerEliquis$36$88,55483 claims
AstraZenecaFarxiga, Brilinta, Symbicort$243$72,96192 claims
GSKTrelegy Ellipta, Anoro Ellipta$148$50,68754 claims
AbbVieCreon, Linzess$27$47,49862 claims
NovartisEntresto$77$21,92522 claims
Astellas Pharma US IncMyrbetriq$20$18,46732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →